Myriad Genetics, Inc. (MYGN)
| Previous Close | 23.31 |
| Open | 23.19 |
| Bid | 22.93 x 1000 |
| Ask | 23.01 x 800 |
| Day's Range | 22.75 - 23.19 |
| 52 Week Range | 13.92 - 28.18 |
| Volume | |
| Avg. Volume | 705,710 |
| Market Cap | 1.849B |
| Beta (5Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.44 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.78 |
- Zacks
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
- Simply Wall St.
A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$19.13 With US$22.90...
- GlobeNewswire
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous rec
